Denali (DNLI) announced that Tim Van Hauwermeiren has been appointed to its Board of Directors. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx (ARGX). Carole Ho, M.D., who has served as Denali’s Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly (LLY) and Company as Executive Vice President, and President of Lilly Neuroscience. Peter Chin, M.D., is assuming the role of Acting Chief Medical Officer and Head of Development at Denali. Dr. Chin is a neurologist and joined Denali in 2019, most recently serving as Senior Vice President of the ETV Franchise and Late-Stage Clinical Development.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics Advances Long-Term Study of Tividenofusp Alfa for MPS II
- Denali Therapeutics Advances FTD Treatment with DNL593 Study
- Denali Therapeutics Advances in MPS II Treatment: A Study Update
- Biogen and Denali’s New Study on LRRK2-Associated Parkinson’s Disease: What Investors Need to Know
- Denali Therapeutics: Buy Rating Affirmed Amid Temporary FDA Delay and Promising Pipeline